Free shipping on all orders over $ 500

Insulin degludec

Cat. No. M22472
Insulin degludec Structure
Size Price Availability Quantity
5mg USD 220  USD220 In stock
10mg USD 350  USD350 In stock
25mg USD 680  USD680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Insulin degludec is an ultra-long-acting form of insulin, shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.

Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells.

In vivo, Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia.

Chemical Information
Molecular Weight 6103.97
Formula C274H411N65O81S6
CAS Number 844439-96-9
Form Solid
Storage -20°C, protect from light, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Amalia Gastaldelli, et al. Lancet Diabetes Endocrinol. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

[2] Tadej Battelino, et al. Lancet Diabetes Endocrinol. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

[3] Bernhard Ludvik, et al. Lancet. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

[4] Ronald M Goldenberg, et al. Diabetes Obes Metab. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia

[5] Roopa Mehta, et al. Diabetes Obes Metab. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines

Related Insulin Receptor Products
AVJ16

AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 to inhibit the migration of H1299 cells with high endogenous IGF2BP1 expression.

[D-Ala2]-GIP (human)

[D-Ala2]-GIP (human) is a GIP receptor agonist.

Gastric Inhibitory Peptide, porcine

Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose metabolism.

(Pro3) GIP, human

(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist.

GIP (3-42), human

GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.

  Catalog
Abmole Inhibitor Catalog




Keywords: Insulin degludec supplier, Insulin Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.